Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Host-cell pathways regulating influenza hemagglutinin (HA) post-translational maturation encompass a series of essential biochemical processes that transform the nascent HA polypeptide into a functional, infectious protein. This maturation occurs within the host's secretory pathway and includes N-linked glycosylation, chaperone-mediated folding (involving calnexin and calreticulin), disulfide bond formation, and trimerization in the endoplasmic reticulum (ER) (Sun & Whittaker, 2013, DOI: 10.1111/j.1600-0854.2012.01456.x). A critical final step is the proteolytic cleavage of the precursor HA0 into HA1 and HA2 subunits by host-cell proteases such as Furin or members of the Type II Transmembrane Serine Protease (TTSP) family, like TMPRSS2 and TMPRSS4, which is a prerequisite for viral membrane fusion and infectivity (Böttcher-Friebertshäuser et al., 2013, DOI: 10.1016/j.virs.2012.11.001). Additionally, palmitoylation of the HA cytoplasmic tail by host ZDHHC enzymes is often required for efficient viral assembly. Targeting these host pathways, rather than the virus itself, represents a host-directed therapeutic strategy aimed at reducing the likelihood of viral resistance. For example, ER glucosidase inhibitors like celgosivir disrupt HA folding, while protease inhibitors like camostat mesylate block the activation of the virus, effectively neutralizing its ability to spread (Warfield et al., 2016, DOI: 10.1371/journal.pone.0150640).
Inhibition of host-cell proteases (e.g., TMPRSS2, Furin) to prevent HA0 cleavage; inhibition of ER glucosidases to disrupt HA folding and trafficking; inhibition of palmitoyltransferases to prevent HA membrane anchoring.
5 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Host-cell pathways regulating influenza hemagglutinin post-translational maturation.